Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy

Fernando J. Martinez (Ann Arbor, United States of America), Fernando J. Martinez, Peter M.A. Calverley, Udo-Michael Goehring, Rachel Hodge, Leonardo M. Fabbri, Klaus F. Rabe

Source: International Congress 2015 – Advances in the future treatment of COPD
Session: Advances in the future treatment of COPD
Session type: Oral Presentation
Number: 482
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Fernando J. Martinez (Ann Arbor, United States of America), Fernando J. Martinez, Peter M.A. Calverley, Udo-Michael Goehring, Rachel Hodge, Leonardo M. Fabbri, Klaus F. Rabe. Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy. Eur Respir J 2015; 46: Suppl. 59, 482

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Effect of roflumilast in patients with severe COPD and a history of hospitalisation
Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017
Year: 2017



Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013



Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014

The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015

Duration of systemic corticosteroids treatment in COPD exacerbations
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008


The adherence to inhaled drugs in COPD patients: Effect on survival
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015

Impact of mucolytic treatment on COPD exacerbations
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013

Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD)
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Increased platelet reactivity during acute exacerbations of COPD, irrespective of antiplatelet therapy
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015

Effect of carbocysteine lysine salt on frequency of exacerbations in COPD patient treated with or without inhaled steroids
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016


Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 526s
Year: 2006

Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Two-year safety of targeted lung denervation in patients with moderate to severe COPD
Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more
Year: 2015

Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006


Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial
Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD
Year: 2005